Trump’s 200% tariff threat on generics will hurt US patients: Indian pharma

Indian pharma warns of US patient crisis

Indian pharmaceutical companies have strongly criticised former US President Donald Trump’s threat to impose a 200% tariff on generic drug imports. Industry leaders say the move, if enacted, would directly harm American patients who depend on affordable medicines from India.

The Indian Pharmaceutical Alliance (IPA) stated that such a tariff would spike drug prices in the US, making essential treatments unaffordable for millions. India supplies nearly 40% of generic medicines consumed in America, including drugs for diabetes, hypertension, and cancer.

Why the threat matters

Trump’s proposal, floated during his election campaign, aims to reduce US dependence on foreign drug manufacturing. However, Indian exporters argue that American companies and patients, not Indian firms, would bear the brunt of the cost.

According to trade data, Indian generics save the US healthcare system over $200 billion annually. A 200% tariff would erase that advantage, forcing US insurers and patients to pay far more for the same medicines.

Supply chain disruptions loom

The IPA warned that the tariff could also disrupt already strained global pharmaceutical supply chains. Many Indian companies operate US-approved facilities and follow strict regulatory standards. A sudden price hike could lead to shortages as smaller US buyers exit the market.

Industry experts note that Indian firms have invested heavily in compliance with US Food and Drug Administration norms. They see the tariff threat as a trade barrier rather than a genuine health policy move.

Industry calls for dialogue

Indian pharma bodies have urged the Indian government to engage diplomatically with the US to avert the tariff. They stress that the issue goes beyond trade—it affects public health outcomes in both countries.

The IPA said that affordable generics are a lifeline for low-income American families, especially those without comprehensive insurance. A tariff hike, they argue, would push many into choosing between medicines and other essentials.

Global trade implications

Legal experts point out that the proposed tariff may violate World Trade Organization rules. India could challenge it at the WTO, but such disputes take years to resolve. Meanwhile, patients would face immediate price increases.

Indian pharma stocks have already seen volatility since the announcement. Companies like Sun Pharma, Dr Reddy’s, and Cipla are closely monitoring the situation.

Health policy analysts in the US have also voiced concern. They say the tariff would undermine decades of bipartisan support for generic drug access.

What happens next depends on the outcome of the US presidential race and subsequent trade negotiations. Indian pharma firms are bracing for uncertainty but remain hopeful that economic pragmatism will prevail over campaign rhetoric.